- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00779051
Bioequivalence Study of Zolpidem 10mg Tablets Under Fasting Conditions
An Open Label, Relative Bioavailability Study of 10 mg Zolpidem Tablet Under Fasting Conditions
Studieoversikt
Detaljert beskrivelse
This was a single-center, randomized, open label, two-way cross over study conducted under fasting conditions. Subjects checked into the clinical facility the day prior to dosing at least 10 hours prior to dose administration. On study day 1, subjects were dosed with single oral dose (1x10mg tablet) of the test and reference products thirty minutes after initiation of a standardized, high fat breakfast which was preceded by an overnight fast. Following a seven day wash out period, subjects returned and were dosed with an alternative treatment as per randomization
Thirty-six (N=36) volunteers were enrolled in the study. Subject 07 elected to withdraw foe personal reasons prior to period II check in. Subject 22 was excluded from statistical analysis due to emesis before twice the median Tmax of reference product
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
North Dakota
-
Fargo, North Dakota, Forente stater, 58104
- PRACS Institute Ltd.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Healthy men or women 18 years of age or older at the time of dosing
- Weights within ±20% for height and body frame as per Desirable weight for adults(1983 Metropolitan Height and Weight table)
- Volunteers judged by the investigator to be healthy based on their medical and medication history, physical examination, electrocardiogram, and clinical laboratory results
- Vounteers willing to participate in the study and have signed a copy of written consent form
- If female:
Of childbearing potential, was practicing an acceptable method of birth control for the duration of study as judged by the investigator(s), such as condom with spermicide, intrauterine device (IUD), or abstinence; or Was menopausal for at least 1year; or Was surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy)
Exclusion Criteria:
Subject candidates must not be enrolled in the study if they meet any of the following criteria:
- Volunteers with a recent history of drug or alcohol addiction or abuse
- Volunteers with the presence of clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the clinical investigators)
- Volunteers with clinical laboratory test values outside the accepted reference range and, when confirmed on re-examination, were deemed to by clinically significant
- Volunteers with a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody
- Volunteers with positive drug abuse screen when screened for the study
- Female volunteers demonstrating a positive pregnancy screen
- Female volunteers who are currently bre ast feeding
- Volunteers with a history of clinically significant allergies including the allergies
- Volunteers with any clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the clinical investigation)
- Volunteers who currently use tobacco products
- Volunteers who had taken any drug known to induce metabolism or inhibit hepatic metabolism in the 28 days prior to the period I dosing.
- Volunteers who reported donating greater than 150 mL of blood within 28 days prior to period I dosing. All subjects were advised not to donate plasma for four weeks after completing the study
- Volunteers who had donated plasma (e.g. plasmapheresis) within 14 days prior to period I dosing. All subjects were advised not to donate plasma for four weeks after completing o the study
- Volunteers who reported receiving any investigational drug within 28 days prior to period I dosing
- Volunteers who reported taking any systemic prescription 14 days prior to Period I dosing
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: 1
Zolipidem 10mg tablets of Ranbaxy
|
|
Aktiv komparator: 2
Ambien® 10mg tablets
|
Hva måler studien?
Primære resultatmål
Resultatmål |
---|
Bioekvivalens
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- R05-274
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Sunn
-
Universidade do PortoFundação para a Ciência e a TecnologiaRekrutteringHealthy People-programmerPortugal
-
VA Office of Research and DevelopmentFullført
-
Universidad Católica del MauleFullført
-
University of MiamiJames and Esther King Biomedical Research ProgramAvsluttetHealthy Lifetime Ikke-røykereForente stater
-
Fundació Institut de Recerca de l'Hospital de la...FullførtHealthy People-programmerSpania
-
University of LeicesterNational Institute for Health Research, United KingdomFullførtPasienter med hjertesvikt og bevart ejeksjonsfraksjon - HFpEF | Pasienter med hjertesvikt med redusert ejeksjonsfraksjon - HFrEF | Healthy Controls Group - alders- og kjønnsmatchet
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesAvsluttetParkinsons sykdom | Healthy Controls Group - alders- og kjønnsmatchetFrankrike
Kliniske studier på Zolpidem 10mg tabletter
-
Northern California Institute of Research and EducationU.S. Army Medical Research and Development CommandFullført
-
Ranbaxy Laboratories LimitedFullført
-
Hanmi Pharmaceutical Company LimitedFullførtPrimær hyperkolesterolemiKorea, Republikken
-
Yokohama City UniversityRekruttering
-
International University of Health and WelfareAvsluttet
-
Chong Kun Dang PharmaceuticalUkjentType II diabetes mellitusKorea, Republikken
-
IlDong Pharmaceutical Co LtdFullført
-
EMSAssociação Fundo de Incentivo à PesquisaFullført
-
South China Center For Innovative PharmaceuticalsXiangya Hospital of Central South UniversityFullført
-
Henry Ford Health SystemFullført